Who owns Spero Therapeutics Inc?
- Ticker: SPRO
- CUSIP Number: 84833t103
Tip: Access positions for across all investors
Analyze quarterly positions in Spero Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Spero Therapeutics stock
Who bought or sold Spero Therapeutics Inc this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Vanguard Group | 1.7M | $2.8M | 1% | Mar 2024 |
|
ADAR1 Capital Management | 927k | $1.6M | -13% | Mar 2024 |
|
Alphabet | 890k | $1.5M | 0% | Mar 2024 |
|
Murchinson | 874k | $1.5M | 1% | Mar 2024 |
|
Acadian Asset Management | 763k | $1.3M | 180% | Mar 2024 |
|
Atlas Venture Life Science Advisors | 608k | $1.0M | -40% | Mar 2024 |
|
BlackRock | 477k | $820k | -1% | Mar 2024 |
|
Geode Capital Management | 469k | $808k | 14% | Mar 2024 |
|
AWM Investment Company | 333k | $573k | 0% | Mar 2024 |
|
Shay Capital | 307k | $528k | 100% | Mar 2024 |
|
Man Group | 214k | $368k | 100% | Mar 2024 |
|
Bridgeway Capital Management | 185k | $318k | 37% | Mar 2024 |
|
Millennium Management | 148k | $254k | -1% | Mar 2024 |
|
DAFNA Capital Management | 125k | $215k | 0% | Mar 2024 |
|
Northern Trust | 115k | $197k | 29% | Mar 2024 |
|
Bank Of Montreal | 80k | $140k | 100% | Mar 2024 |
|
Squarepoint Ops | 79k | $137k | -35% | Mar 2024 |
|
Bailard | 61k | $105k | 100% | Mar 2024 |
|
DLK Investment Management | 31k | $54k | 0% | Mar 2024 |
|
Charles Schwab Investment Management | 29k | $49k | 0% | Mar 2024 |
|
Mackenzie Financial | 28k | $49k | 33% | Mar 2024 |
|
GSA Capital Partners | 28k | $49k | 100% | Mar 2024 |
|
Susquehanna International | 20k | $34k | -3% | Mar 2024 |
|
Virtu Financial | 18k | $31k | 100% | Mar 2024 |
|
XTX Topco | 15k | $26k | -74% | Mar 2024 |
|
Dimensional Fund Advisors | 10k | $17k | 0% | Mar 2024 |
|
Yale Capital Corp. | 10k | $17k | 0% | Mar 2024 |
|
Morgan Stanley | 7.9k | $13k | -12% | Mar 2024 |
|
Russell Investments | 6.4k | $11k | 0% | Mar 2024 |
|
UBS Group | 5.7k | $9.9k | 1641% | Mar 2024 |
|
Bank of America Corporation | 5.2k | $8.9k | -10% | Mar 2024 |
|
FMR | 2.4k | $4.1k | 100% | Mar 2024 |
|
Hanson McClain Advisors | 600.00 | $1.0k | 0% | Mar 2024 |
|
Wells Fargo & Company | 540.00 | $928.800000 | 1% | Mar 2024 |
|
Raleigh Capital Management | 500.00 | $860.000000 | 100% | Mar 2024 |
|
Rhumbline Advisers | 458.00 | $786.981400 | 0% | Mar 2024 |
|
Jpmorgan Chase & Co | 236.00 | $405.990800 | 0% | Mar 2024 |
|
Tower Research Capital | 216.00 | $371.995200 | -62% | Mar 2024 |
|
Us Bancorp | 151.00 | $260.006900 | 0% | Mar 2024 |
|
Goss Wealth Management | 100.00 | $172.000000 | 0% | Mar 2024 |
|
PFS Partners | 50.00 | $86.000000 | 0% | Mar 2024 |
|
Advisor Group Holdings | 47.00 | $80.999800 | -52% | Mar 2024 |
|
Federation des caisses Desjardins du Quebec | 30.00 | $51.999000 | 100% | Mar 2024 |
|
Bnp Paribas Arbitrage, Snc | 12.00 | $21.000000 | 0% | Mar 2024 |
|
Qube Research & Technologies | 1.00 | $2.000000 | 0% | Mar 2024 |
|
Who sold out of Spero Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Ameriprise Financial | Sep 2023 | 464k | $561k |
Rock Springs Capital Management | Sep 2023 | 57k | $69k |
Group One Trading | Sep 2023 | 34k | $41k |
Citadel Advisors | Dec 2023 | 32k | $47k |
Bourgeon Capital Management | Dec 2023 | 15k | $22k |
Two Sigma Securities | Dec 2023 | 10k | $15k |
Royal Bank of Canada | Dec 2023 | 315.00 | $0 |